BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36764804)

  • 1. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2023 Mar; 43(1):115-125. PubMed ID: 36764804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2021 Sep; 41(3):485-495. PubMed ID: 34304777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
    Chen X; Gao Q; Roshal M; Cherian S
    Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
    Cherian S; Soma LA
    Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Girase K; Verma S; Arolkar G; Dasgupta N; Narula G; Shetty D; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
    Br J Haematol; 2022 Jan; 196(2):374-379. PubMed ID: 34476808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.
    Borowitz MJ; Wood BL; Keeney M; Hedley BD
    Curr Protoc; 2022 Mar; 2(3):e383. PubMed ID: 35263042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Lebecque B; Besombes J; Dannus LT; De Antonio M; Cacheux V; Grèze V; Montagnon V; Veronese L; Tchirkov A; Tournilhac O; Berger MG; Veyrat-Masson R
    Br J Haematol; 2024 May; 204(5):1872-1881. PubMed ID: 38432068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
    Shaver AC; Seegmiller AC
    Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Minimal Residual Disease in B Cell Acute Lymphoblastic Leukemia Using an Eight-Color Tube with Dried Antibody Reagents.
    Bouriche L; Bernot D; Nivaggioni V; Arnoux I; Loosveld M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):158-163. PubMed ID: 30698327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
    Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
    Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Verbeek MWC; van der Velden VHJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Liu Z; Li Y; Shi C
    Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.